Jul 9, 2026 | Blog
In clinical research, few words carry more operational risk than “ready.” A site may be described as ready when a Research Ethics Committee or Institutional Review Board has approved the protocol. A network may be described as ready when a master agreement is in...
Jul 2, 2026 | Blog
For decades, discussions about equity in global clinical research have often focused on the terms of partnership, who owns the data, who leads publications, who holds intellectual property, and who captures the economic value created by research. These are important...
Jun 25, 2026 | Blog
Most scaling plans for clinical research in Africa describe expansion. Fewer describe integration. Expansion adds sites, countries, investigators, and trials. Integration is the harder work of making those additions function as a single operational system. The...
May 29, 2026 | Blog
When a clinical trial in Africa stalls, the explanation is often immediate: “regulatory delay.” It is a convenient phrase. It is also too often an incomplete one. “Regulatory delay” can mean many different things. It can mean a regulator took longer than expected. It...
May 26, 2026 | Blog
Strategic relevance in global clinical research is not granted. It is earned. Every sponsor has a line in its portfolio strategy. Above that line sit the countries and sites trusted with pivotal trials, adaptive designs, first-in-human studies and complex oncology...
May 15, 2026 | Blog
By now, the argument for Africa’s inclusion in global clinical research is well established. The scientific rationale is clear. The public health need is clear. The access imperative is clear. But sponsors do not place complex Phase II and III trials solely on the...
